Address correspondence to Dr Jeffrey Rakofsky, 12 Executive Park Dr, Room 348, Atlanta, GA 30329, firstname.lastname@example.org.
RELATIONSHIP DISCLOSURE: Dr Rakofsky receives research/grant support from ACADIA Pharmaceuticals Inc; the American Board of Psychiatry and Neurology; Assurex Health; AstraZeneca; Janssen Global Services, LLC; the National Institute of Mental Health (RO1MH073719-05A1, 7R01MH104964-02); and the National Center for Complementary and Integrative Health (1UG3AT008857). Dr Rapaport serves as editor-in-chief of Focus: The Journal of Lifelong Learning in Psychiatry and on the editorial boards of CNS Neuroscience and Therapeutics; CNS Spectrums; Current Psychiatry; Depression Research and Treatment; Innovations in Clinical Neuroscience; Journal of Addictive Behaviors, Therapy & Rehabilitation; The Journal of Clinical Psychiatry; and Shanghai Archives of Psychiatry. Dr. Rapaport receives research/grant support from the National Center for Complementary and Integrative Health (UG3 AT008857-01, R01 AT009169-01) and the National Institute of Mental Health (MH100023-01, 1R25MH101079-01).
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Rakofsky and Rapaport discuss the unlabeled/investigational use of buspirone, pramipexole, and thyroid hormone as adjuncts to an antidepressant in the treatment of major depression and ketamine for treatment-resistant patients who are depressed and suicidal.
CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE